- Perrigo to buy Elan Corp.
- Perrigo to acquire Fera's ophthalmic portfolio for up to $129 million
- Perrigo recalls APAP infant suspension liquid due to the possibility of missing dose markings on the dosing syringe
- FDA approves Perrigo's fluticasone propionate lotion
- Report: Kroger adding 2,000 jobs across Michigan
ALLEGAN, Mich. — The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.
Perrigo said that Cobrek, with which it is partnering, had received approval for betamethasone validate foam in the 0.12% strength. The drug is a generic version of Luxiq foam, made by GlaxoSmithKline subsidiary Stiefel Labs, and is used to treat corticosteroid-responsive skin conditions of the scalp, also known as scalp psoriasis.
The branded version of the drug has annual sales of about $40 million, according to Perrigo.